

TECHNOLOGIEPARK BASEL

Zielgruppe des Technologieparks Basel sind innovative Jungunternehmen aus der Life Sciences-Industrie, der chemischen Industrie, der Umwelt- und Energietechnologie, der Nanotechnologie sowie der Informations- und Kommunikationstechnologie. Die Unternehmen werden auf Basis ihres Innovationspotenzials sowie ihres Potenzials, mittelfristig Arbeitsplätze in der Region zu schaffen und Wertschöpfung zu generieren, ausgewählt.

Der kommerzielle Start dieser Jungunternehmen aus Hochtechnologiebranchen wird durch das Angebot von Büro-, Labor- und Lagerflächen sowie Infrastrukturen zur gemeinschaftlichen Nutzung vereinfacht. Zudem stellt der Technologiepark Basel grundlegende Dienstleistungen zur Verfügung.

Erfolgreiche Jungunternehmen bleiben oft nur wenige Jahre im Technologiepark Basel. Nach Etablierung des Unternehmens und dessen Produkten im Markt finden die Unternehmen einen neuen Standort im regionalen Immobilienmarkt.

Der Technologiepark Basel ist nicht gewinnorientiert, sondern ist ein Instrument der baselstädtischen Standortförderung. Im Verbund mit weiteren Instrumenten leistet er einen Beitrag zur Erhöhung der Zahl der in der Region Basel neu gegründeten Hochtechnologie-Unternehmen.

ERSTE UND ZWEITE ERWEITERUNG TECHNOLOGIEPARK BASEL

Aufgrund der grossen Nachfrage und um den Expansionsplänen der bestehenden Mieter gerecht zu werden, wurde der Technologiepark Basel im Sommer 2014 zum ersten Mal erweitert. Neben einer Verdopplung der Labor- und Büroflächen wurden auch ein zentraler Empfangsbereich sowie ein Auditorium erstellt.

Die anhaltend hohe Auslastung der Labor- und Büroflächen im Technologiepark Basel sowie die Verfügbarkeit von freien Flächen im gleichen Gebäude haben dazu geführt, dass der Regierungsrat und der Grosse Rat des Kantons Basel-Stadt einer zweiten Erweiterung des Technologieparks Basel zugestimmt haben. Anfang 2018 wurde die Fläche um weitere 12 Biologie- und 2 Chemielabors, 34 Büros sowie weitere Gemeinschaftsräume (Sitzungszimmer, Küche, Aufenthaltsbereiche sowie Geräte- und Waschräume) erweitert, so dass der Technologiepark Basel aktuell gesamthaft rund 6400 m² Fläche umfasst.

FACTS & FIGURES

Juristische Einheit

Technologiepark Basel AG, gegründet am 31. März 2011

Eigentümer & Aktionär

Kanton Basel-Stadt

Verwaltungsrat

Samuel Hess (Präsident), Robert-Jan Bumbacher (Vizepräsident), Nina Ryser-Iten (Mitglied)

Geschäftsleitung und Team

Der Verwaltungsrat delegiert die Geschäftsleitung des Technologieparks Basel an Nina Ryser-Iten (Leitung Standortförderung im Amt für Wirtschaft und Arbeit). Weiter sind Christian Harr (Operativer Leiter), Brigitte Jäggi (Administration), Güney Talas (Empfang) und Giovanni Attianese (Techn. Mitarbeiter) für den Technologiepark Basel tätig.

Eröffnung des Technologieparks Basel

Sommer 2011, 1. Erweiterung Sommer 2014, 2. Erweiterung Anfang 2018

Vermietungsstand per 28. Februar 2019

72%

Fläche

Seit Sommer 2014: ca. 3400 m²

Seit Anfang 2018: ca. 6400 m²

Mietflächen

Büroflächen ab 12m²

Laborflächen ab 43m²

Mietpreise

Die Mietpreise im Technologiepark Basel liegen auf Marktniveau. Der Technologiepark Basel bietet innovativen Jungunternehmen aber zum Beispiel durch kurze Kündigungsfristen, der Verfügbarkeit von kleinen Mietflächen und der unentgeltlichen Vorhaltung von Expansionsflächen vorteilhafte Mietkonditionen.

Partner

Kanton Basel-Stadt, Swisscom

Kontakt

Technologiepark Basel AG

Hochbergerstrasse 60C

4057 Basel

Tel.: +41 61 633 22 00

www.technologiepark.ch

Mieter im Technologiepark



BioVersys AG, www.bioversys.com

BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics. We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC's (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.



NBE-Therapeutics GmbH, www.NBE-Therapeutics.com

NBE-Therapeutics is a new Swiss Life-Sciences company focused on the development of novel antibody-based therapeutics. NBE-Therapeutics utilizes a portfolio of in-house developed, externally acquired, and in-licensed novel patent families for the development of novel, best-in-class antibody drug conjugates (ADCs), that can specifically target cancer cells for destruction.



Ramirez Engineering GmbH, www.ramirez-eengineering.ch

Ramirez Engineering GmbH is a Hard- & Firmware Engineering company, specialized in standard and custom specific developments. In addition to devices for Industrial applications, we are also specialized in developing and manufacturing KNX devices, the worldwide standard for home and building control. In this way, we help reducing energy waste in Offices and Hotels Worldwide.



abel-systems, www.abel-systems.ch

abel-systems is a software engineering and IT consulting company specialized in custom web and mobile development. abel-systems develops and distributes the process- and document-management solution QM-Pilot. Furthermore we provide IT solutions for content management, web and mobile apps, as well as the development of individual solutions with modern technologies.



Intilaris LifeSciences GmbH, www.intilaris.com

Intilaris LifeSciences is a life science company focusing on productivity improvements and optimizations in Clinical development of pharmaceutical companies. The company provides GCP consulting and develops tools and systems that will lead to better utilization of the current resources and optimization of the clinical development processes. The customers of intilaris LifeSciences are the Clinical Development organizations of research oriented pharmaceutical companies. To a wider extend, intilaris LifeSciences serves the Clinical Development organizations of research oriented biotechnology companies as well.



Cray Computer GmbH, www.cray.com

As a global leader in supercomputing, Cray provides highly advanced systems and solutions and world-class service and support to government, industry and academia. Cray technology enables scientists and engineers to not only meet existing and future simulation and analytics challenges but achieve remarkable breakthroughs by accelerating performance, improving efficiency and extending the capabilities of their most demanding applications.



Hutman Diagnostics AG, www.hutman.com

Hutman Diagnostics is an *in Vitro* Diagnostics Product Development and Portfolio Management Company in particular, Hutman Diagnostics develops next generation diagnostic kits for life-threatening pathogens so far diagnosed mainly by classical culture. The new diagnostics shorten the time for medical decision to less than 4 hours while having inclusivity of nearly 100%. This will save health costs and shorten the time to cure.



FGen GmbH, www.fgen.ch

FGen is a service provider for biotechnology, life-sciences, and industry. The company was founded in 2011 by Prof. Sven Panke (Bioprocess Laboratory of the Department of Biosystems Science and Engineering of the ETH Zurich in Basel) and a number of his scientific fellows. FGen develops and performs high throughput experiments and assays on a contract basis for its customers from biotech, pharma, and chemical industries.



STREKIN AG, www.strekin.com

Strekin AG is a private company located in Basel. We identify and develop differentiated medicines for diseases linked to stress related inflammatory pathways by scientific cross disease area target assessment.



Cellestia Biotech S.A., www.cellestiaibotech.com.com

Cellestia Biotech S.A. is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signalling pathway. CB-103 is a novel, first-in-class, oral pan-Notch inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.



AUREALIS PHARMA

Aurealis Pharma AG., www.aurealispharma.com

Aurealis Pharma is a Swiss-Finnish biopharmaceutical company with a technology platform facilitating combination therapy embedded in one single product that can be administered in a safe, efficient and cost-effective way. Safe food-grade lactic acid bacteria release multiple therapeutic human proteins locally in diseased tissue. Our first products are immuno-therapeutics to treat patients with chronic inflammatory wounds and cancer indications.



Halozyme Switzerland GmbH., www.halozyme.com

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to treating cancer, PEGPH20 may help make existing treatments more effective by allowing therapies to reach the tumor.

EdelweissConnect

Edelweiss Connect GmbH., <https://www.edelweissconnect.com>

Edelweiss Connect manages collaborative projects to achieve goals in scientific research, infrastructure development or service provision. Edelweiss Connect acts both as the initiator of independent research projects (eg. in Discovery Informatics, Knowledge Management, Life Sciences, Drug Safety, Environmental Chemistry, Risk Assessment) and as a provider of integrated services for corporate clients in these areas.

VAXIMM

Vaximm AG., www.vaximm.com

VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM's technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.



Ridgeline Therapeutics AG., www.ridgelinetherapeutics.com

Ridgeline is Versant's newest discovery engine and has laboratories in Basel Technology Park. Ridgeline's leadership team hails from Roche and has a proven track record in drug development



SIP DayOne, www.dayone.swiss

DayOne - the innovation hub for precision medicine has a vision to “Create a world leading precision medicine hub respected for its impact and collaboration across silos.”



KINARUS AG, www.kinarus.com

KINARUS AG is a private company located in Basel. We identify and develop differentiated medicines for diseases linked to stress related inflammatory pathways by scientific cross disease area target assessment.



TargImmune Therapeutics AG, www.targimmune.com

TargImmune Therapeutics AG is a startup company established in March 2016 in Basel, Switzerland. TargImmune is developing a novel cancer-targeted platform technology CTPIC in the field of immuno-oncology and personalized therapy



Health Care Systems Schweiz GmbH (HCSG), www.hcsg.de

Making patient data smart - HCSG offers solutions for digital precision medicine.

We combine medical data with psychosocial data creating actionable information and risk predictions to improve individual health outcomes. Our highly flexible IT platform allows large scale implementation for a multitude of patient conditions and care situations.



ARTIDIS AG, www.artidis.com

ARTIDIS AG focuses on development and commercialization of ARTIDIS (AUTOMATED AND RELIABLE TISSUE DIAGNOSTICS) nanotechnology platform for rapid diagnostics and treatment optimization. ARTIDIS is based on the atomic force microscope, which can determine the (nano)mechanical properties of native tissue by using a fine, nanometer-scale probe. able to examine tissue biopsies within an hour. By providing such nanomechanical profile of patient biopsy sample, ARTIDIS allows for rapid diagnosis of benign or malignant tumors and consequently optimization of treatment for cancer patients.

Texelia AG, www.texelia.com



Texelia delivers IT expertise and project management to the most demanding organizations. By helping leaders in research, innovation and high-quality delivery, we contribute to the production of common goods which are central to sustainable well-being, such as health, mobility and public services.

Texelia means Technology, Excellence and Accuracy: it is the new name of Swiss ventures with a 25 years history of customer satisfaction in the pharmaceutical, chemical and nutrition industries as well as in transport and public administrations. Our clients are renowned organizations with a worldwide reach and reputation.

Data Coordination Centre



Swiss Personalized Health Network, www.dcc.sib.swiss

The Swiss Personalized Health Network (SPHN) is a national initiative promoting the development of personalized health research. The Data Coordination Centre (DCC), operated by the SIB Swiss Institute of Bioinformatics (SIB), coordinates activities in the fields of clinical medicine, academic research and IT to achieve nationwide interoperability of health data.

ABBA Therapeutics AG,



ABBA Therapeutics is a privately owned Swiss biotech company established in Basel in 2015. ABBA Therapeutics is committed to developing novel antibody drugs to modulate immune recognition and activation for anti-cancer therapy.

Skyhawk Therapeutics Europa GmbH, <https://www.skyhawktx.com>



Skyhawk Therapeutics, with laboratories in Boston (U.S.) and the Basel Technology Park, is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression. Our founders are leading experts in developing small molecule therapeutics for RNA-based disease. Our first drug candidates are targeted towards cancers and neurological conditions, some of which were previously considered undruggable.



Versameb AG, <https://versameb.com>

Versameb is a Swiss based biotechnology platform company focusing on the optimized local delivery of therapeutic proteins, currently focusing on applications in regenerative medicine. Our vision is to both improve existing therapies as well as develop transformative therapies in entirely new applications in disease indications of high medical need. Versameb is funded by private international investors. We are committed to create substantial long-term value for our patients, shareholders and other stakeholders.